相似文献
1
In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01798-16. Print 2017 Feb.
2
activity of bedaquiline against complex.
J Med Microbiol. 2021 Oct;70(10). doi: 10.1099/jmm.0.001439.
3
Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
J Glob Antimicrob Resist. 2024 Jun;37:135-140. doi: 10.1016/j.jgar.2024.03.009. Epub 2024 Mar 30.
4
In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
J Clin Microbiol. 2013 Oct;51(10):3389-94. doi: 10.1128/JCM.01612-13. Epub 2013 Aug 14.
5
Difference in drug susceptibility distribution and clinical characteristics between and lung diseases in Shanghai, China.
J Med Microbiol. 2021 May;70(5). doi: 10.1099/jmm.0.001358.
6
Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
J Infect Chemother. 2018 Apr;24(4):315-318. doi: 10.1016/j.jiac.2017.10.022. Epub 2017 Dec 7.
7
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.
8
Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
J Infect Chemother. 2019 Dec;25(12):995-1000. doi: 10.1016/j.jiac.2019.05.028. Epub 2019 Jun 22.
9
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
10
In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
J Microbiol Immunol Infect. 2018 Oct;51(5):636-643. doi: 10.1016/j.jmii.2017.05.001. Epub 2017 Jun 28.
引用本文的文献
1
Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against in the hollow-fiber system.
Antimicrob Agents Chemother. 2025 May 7;69(5):e0146424. doi: 10.1128/aac.01464-24. Epub 2025 Apr 14.
2
Curcumin enhances bedaquiline's efficacy against : and evidence.
Microbiol Spectr. 2025 Mar 18;13(5):e0229524. doi: 10.1128/spectrum.02295-24.
3
Treatment for non-tuberculous mycobacteria: challenges and prospects.
Front Microbiol. 2024 Jun 3;15:1394220. doi: 10.3389/fmicb.2024.1394220. eCollection 2024.
4
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.
J Antimicrob Chemother. 2024 Feb 1;79(2):211-240. doi: 10.1093/jac/dkad372.
5
In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing and Clinical Isolates.
Antibiotics (Basel). 2023 Sep 6;12(9):1409. doi: 10.3390/antibiotics12091409.
6
Variability of Complex Isolates Drug Susceptibility Testing by Broth Microdilution.
Antibiotics (Basel). 2022 Dec 4;11(12):1756. doi: 10.3390/antibiotics11121756.
7
Development of Human Cell-Based Infection Models to Determine the Intracellular Survival of .
Front Cell Infect Microbiol. 2022 Jun 24;12:872361. doi: 10.3389/fcimb.2022.872361. eCollection 2022.
8
In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.
BMC Microbiol. 2022 Jul 8;22(1):175. doi: 10.1186/s12866-022-02582-2.
9
Looking beyond Typical Treatments for Atypical Mycobacteria.
Antibiotics (Basel). 2020 Jan 3;9(1):18. doi: 10.3390/antibiotics9010018.
10
Inhaled Antibiotics for Mycobacterial Lung Disease.
Pharmaceutics. 2019 Jul 19;11(7):352. doi: 10.3390/pharmaceutics11070352.
本文引用的文献
1
Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.
Chest. 2015 Aug;148(2):499-506. doi: 10.1378/chest.14-2764.
2
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21.
3
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
Eur Respir J. 2015 Feb;45(2):554-7. doi: 10.1183/09031936.00142914. Epub 2014 Oct 30.
4
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15.
5
Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.
6
FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385.
7
Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2014 May;58(5):2979-81. doi: 10.1128/AAC.00037-14. Epub 2014 Mar 3.
8
Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Chest. 2014 Aug;146(2):276-282. doi: 10.1378/chest.13-2538.
9
Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.
Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13. Epub 2013 Sep 23.
10
Bedaquiline: First FDA-approved tuberculosis drug in 40 years.
Int J Appl Basic Med Res. 2013 Jan;3(1):1-2. doi: 10.4103/2229-516X.112228.
Zotero 插件